Precipio to Present Superior Cancer Diagnostic Assay at ASH Meeting.

Precipio, a cancer diagnostics company, will present findings from a joint study with Memorial Sloan Kettering at ASH. The study evaluated Precipio's BCR::ABL1 assay, demonstrating superior performance and concordance with leading platforms. The study included 895 patient samples and showed clear patient care benefits and improved laboratory workflows. The poster presentation and results discussion are scheduled for December 8th at the ASH Meeting in Orlando.